Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

TCGA-E9-A1QZ-01A-21R-A169-07

— · A

516f529b-e9e8-5680-8bf1-bcc8df49e3e8

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A
overall_survival_months
25

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_GAMMA_RESPONSE+0.560
  • INTERFERON_ALPHA_RESPONSE+0.550
  • ALLOGRAFT_REJECTION+0.470
  • ADIPOGENESIS+0.430
  • IL6_JAK_STAT3_SIGNALING+0.430
  • BILE_ACID_METABOLISM+0.380
  • COMPLEMENT+0.380
  • FATTY_ACID_METABOLISM+0.380
  • TNFA_SIGNALING_VIA_NFKB+0.380
  • APOPTOSIS+0.360

Top 10 suppressed

  • MYC_TARGETS_V2-0.460
  • GLYCOLYSIS-0.220
  • UNFOLDED_PROTEIN_RESPONSE-0.220
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.130
  • MITOTIC_SPINDLE-0.130
  • PANCREAS_BETA_CELLS-0.100
  • HEDGEHOG_SIGNALING-0.070
  • ANGIOGENESIS-0.050
  • APICAL_JUNCTION-0.050
  • MYC_TARGETS_V1-0.030

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR12696766
melanoma-umap@29
——0.842
2sclcWD9900_S48.txt
lung-landscapes@6
—cohortA10.841
3SRR4195658
colon-landscapes@1
——0.838
4C3N-01416
lung-landscapes@6
—cohortA10.837
520020049.LumB
breast-umap@18
—D0.832
6MBCProject_3808_T3_RNA
breast-umap@18
—A0.825
7SRR6013535
lung-landscapes@6
—cohortMD20.811
820110002.Her2HRneg
breast-umap@18
—D0.808
9TCGA-75-5126-01A-01R-1755-07
lung-landscapes@6
—cohortA10.807
10BS_HQ5BJ6MW
brain-umap@2
pilocytic astrocytoma—0.804

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 38 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_GAMMA_RESPONSE0.560Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.550Inavolisib— uncovered
ALLOGRAFT_REJECTION0.470Idelalisib— uncovered
ADIPOGENESIS0.430Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.430Inavolisib— uncovered
BILE_ACID_METABOLISM0.380Inavolisib— uncovered
COMPLEMENT0.380Inavolisib— uncovered
FATTY_ACID_METABOLISM0.380Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.380Inavolisib— uncovered
APOPTOSIS0.360Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.350Idelalisib— uncovered
KRAS_SIGNALING_UP0.320Inavolisib— uncovered
IL2_STAT5_SIGNALING0.300Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.270Inavolisib— uncovered
HEME_METABOLISM0.250Temsirolimus— uncovered
PEROXISOME0.250Idelalisib— uncovered
PROTEIN_SECRETION0.250Remibrutinib— uncovered
ANDROGEN_RESPONSE0.230Inavolisib— uncovered
COAGULATION0.200Binimetinib— uncovered
PI3K_AKT_MTOR_SIGNALING0.190Inavolisib— uncovered